Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at ... et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary ...

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial Receive the the latest news, research, and presentations from major ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) showcased encouraging results from the Phase 2b SEISMiC study of istaroxime, its novel investigational therapy for early cardiogenic shock, at the ...

Elevating patients with cardiogenic shock (CS) to mechanical circulatory support (MCS) early on could yield greater reductions in mortality due to CS, as opposed to the strategy of managing ...

The study, titled "Hemodynamic Effects of Intravenous Istaroxime in Patients with SCAI Stage B Cardiogenic Shock: Insights from the SEISMiC Trial," highlighted istaroxime's ability to improve ...

The SEISMiC study focused on the effects of istaroxime in patients experiencing early (SCAI Stage B) cardiogenic shock, a condition marked by dangerously low blood pressure and the risk of ...

Cardiogenic shock occurs when the heart is not able to pump enough blood to generate adequate cardiac output to maintain normal blood pressure. This frequently occurs in the setting of a large ...

The SEISMiC study focused on the effects of istaroxime in patients experiencing early (SCAI Stage B) cardiogenic shock, a condition marked by dangerously low blood pressure and the risk of ...